Evaluation of Minnesota Score in the Allocation of Venovenous Extracorporeal Membrane Oxygenation During Resource Scarcity
Table 1
Demographics and comorbidities of patients treated with venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome with and without COVID-19.
Characteristic
All patients n = 124
Without COVID-19 n = 77
With COVID-19 n = 47
value
Age, median (IQR)
48 (38–57)
43 (34–57)
53 (46–57)
0.006
Sex, n (%)
Male
91 (73)
51 (66)
40 (85)
0.014
Race, n (%)
American Indian
3 (2)
2 (3)
1 (2)
<0.001
Asian
8 (6)
3 (4)
5 (11)
Black
21 (17)
10 (13)
11 (49)
White, Hispanic
20 (16)
4 (5)
16 (34)
White, non-Hispanic
66 (53)
52 (68)
14 (30)
BMI, mean (SD)
31 (7)
31 (7)
32 (6)
0.86
Comorbidity, n (%)
Obesity
68 (55)
42 (55)
26 (55)
0.93
Tobacco use
52 (42)
44 (57)
8 (17)
<0.001
Hypertension
42 (34)
23 (30)
19 (40)
0.22
Diabetes mellitus
30 (24)
13 (17)
17 (36)
0.02
Hyperlipidemia
28 (23)
16 (21)
12 (26)
0.54
Asthma
13 (10)
10 (13)
3 (6)
0.24
COPD
12 (10)
10 (13)
2 (4)
0.11
Coronary artery disease
10 (8)
7 (9)
3 (6)
0.59
Chronic kidney disease
9 (7)
5 (6)
4 (9)
0.67
SOFA, mean (SD)
8 (3)
9 (3)
7 (2)
<0.001
RESP, mean (SD)
2.2 (3.1)
2.2 (3.0)
2.2 (3.3)
0.98
Disposition, n (%)
Home
15 (14)
12 (17)
3 (7)
0.12
Rehabilitation
48 (43)
31 (45)
17 (40)
0.65
In-hospital mortality, n (%)
47 (38)
29 (38)
18 (38)
0.94
SOFA, sequential organ failure assessment score; RESP, respiratory ECMO survival prediction score; BMI, body mass index; COPD, chronic obstructive pulmonary disease; COVID-19, severe acute respiratory syndrome coronavirus 2. .
